TERN-701

Small molecule

TTerns, Inc.

TERN-701 is one of 45 small molecule programs targeting Myeloid Leukemia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloid LeukemiaActive, not recruiting

Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

100 competitors in Myeloid Leukemia

#DrugCompanyPhaseTrials

Iclusig

Takeda

Phase 3

6 2

Trexall

Alnylam Pharmaceuticals

Phase 3

2 3

Xospata

Astellas

Phase 3

—4

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

39 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

1 6

Busulfex

Akero Therapeutics

Phase 3

1 7

Scemblix

Novartis

Phase 2

5 8

Jakafi

Incyte

Phase 2

3 9

Actos

Takeda

Phase 2

3 10

Cytosar

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1/2Recruiting

Myeloid Leukemia

NCT06163430

Clinical

Trials by Indication[1]

Myeloid Leukemia1 trial

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

Recruiting·TTerns, Inc.·Phase 1/2·NCT06163430·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TERN-701. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TERN-701 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TERN-701. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Terns, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: TTerns, Inc.

TERN-701

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News